Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc - Registered Shares

11
NAS:BMRN (USA)   Registered Shares
$ 90.68 +0.58 (+0.64%) 10:09 PM EST
102.39
P/B:
3.43
Market Cap:
$ 17.00B
Enterprise V:
$ 17.02B
Volume:
1.23M
Avg Vol (2M):
1.32M
Also Trade In:
Volume:
1.23M
Avg Vol (2M):
1.32M

Business Description

Biomarin Pharmaceutical Inc logo
Biomarin Pharmaceutical Inc
NAICS : 325412 SIC : 2834
ISIN : US09061G1013

Share Class Description:

BMRN: Registered Shares
Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Name Current Vs Industry Vs History
Cash-To-Debt 0.98
Equity-to-Asset 0.72
Debt-to-Equity 0.22
Debt-to-EBITDA 3.54
Interest Coverage 9.44
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.07
Distress
Grey
Safe
Beneish M-Score -2.14
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 65.42
9-Day RSI 58.4
14-Day RSI 53.05
6-1 Month Momentum % -2.96
12-1 Month Momentum % -11.98

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.51
Quick Ratio 1.57
Cash Ratio 0.91
Days Inventory 698.71
Days Sales Outstanding 86.77
Days Payable 197.2

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.2
Shareholder Yield % -0.02

Financials (Next Earnings Date:2024-04-26 Est.)

BMRN's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BMRN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biomarin Pharmaceutical Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2,419.226
EPS (TTM) ($) 0.88
Beta 0.38
Volatility % 25.07
14-Day RSI 53.05
14-Day ATR ($) 2.156601
20-Day SMA ($) 88.704
12-1 Month Momentum % -11.98
52-Week Range ($) 76.02 - 102.96
Shares Outstanding (Mil) 188.68

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomarin Pharmaceutical Inc Filings

Filing Date Document Date Form
No Filing Data

Biomarin Pharmaceutical Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Biomarin Pharmaceutical Inc Frequently Asked Questions

What is Biomarin Pharmaceutical Inc(BMRN)'s stock price today?
The current price of BMRN is $90.68. The 52 week high of BMRN is $102.96 and 52 week low is $76.02.
When is next earnings date of Biomarin Pharmaceutical Inc(BMRN)?
The next earnings date of Biomarin Pharmaceutical Inc(BMRN) is 2024-04-26 Est..
Does Biomarin Pharmaceutical Inc(BMRN) pay dividends? If so, how much?
Biomarin Pharmaceutical Inc(BMRN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1